12/19
07:30 am
ogn
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
Low
Report
Organon To Present at the 43rd Annual J.P. Morgan Healthcare Conference
12/16
07:30 am
ogn
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Medium
Report
FDA Approves VTAMA® (tapinarof) cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
12/10
08:14 am
ogn
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now? [Yahoo! Finance]
12/9
10:49 am
ogn
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]
Low
Report
Organon & Co. (OGN) Is a Trending Stock: Facts to Know Before Betting on It [Yahoo! Finance]
11/26
07:05 am
ogn
Organon & Co. (OGN): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
Low
Report
Organon & Co. (OGN): An Oversold Healthcare Stock to Invest In Now [Yahoo! Finance]
11/13
08:31 am
ogn
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) [Seeking Alpha]
Low
Report
Organon: Certainly A Risky Bet, But Looks Increasingly Compelling (Upgrade) [Seeking Alpha]
11/5
07:29 am
ogn
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
Low
Report
Update on FDA Review of VTAMA® (tapinarof) Cream, 1% for the Treatment of Atopic Dermatitis in Adults and Children 2 Years of Age and Older
11/4
10:47 am
ogn
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know [Yahoo! Finance]
Low
Report
Investors Heavily Search Organon & Co. (OGN): Here is What You Need to Know [Yahoo! Finance]
10/31
07:30 am
ogn
Organon Reports Results for the Third Quarter Ended September 30, 2024
Low
Report
Organon Reports Results for the Third Quarter Ended September 30, 2024
10/30
06:00 am
ogn
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
Low
Report
US FDA Accepts Biologics License Application (BLA) for HLX14, Biosimilar Candidate of PROLIA/XGEVA (denosumab)
10/28
10:45 am
ogn
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics [Yahoo! Finance]
Low
Report
Ahead of Organon (OGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics [Yahoo! Finance]
10/28
09:25 am
ogn
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
Low
Report
Organon Completes Acquisition of Dermavant, including Innovative Dermatologic Therapy, VTAMA® (tapinarof) Cream, 1%
10/25
10:47 am
ogn
Do Options Traders Know Something About Organon (OGN) Stock We Don't? [Yahoo! Finance]
Low
Report
Do Options Traders Know Something About Organon (OGN) Stock We Don't? [Yahoo! Finance]
10/9
07:30 am
ogn
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
Low
Report
Organon to Report Third Quarter 2024 Results and Host Conference Call on October 31, 2024
10/3
07:56 am
ogn
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now? [Yahoo! Finance]
Low
Report
Is WisdomTree U.S. SmallCap Dividend ETF (DES) a Strong ETF Right Now? [Yahoo! Finance]
9/30
02:34 pm
ogn
Organon reports positive phase 3 results on Roche Perjuta biosimilar [Seeking Alpha]
Low
Report
Organon reports positive phase 3 results on Roche Perjuta biosimilar [Seeking Alpha]
9/30
06:00 am
ogn
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
Low
Report
Primary Endpoint Met in Phase 3 Comparative Clinical Study of Perjeta® (pertuzumab) Biosimilar Candidate HLX11
9/25
07:40 am
ogn
Organon & Co. (NYSE: OGN) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Medium
Report
Organon & Co. (NYSE: OGN) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.